Swiss Quality of Life and Health Care Impact Assessment in a Real‐World Erenumab‐Treated Migraine Population: Results over 2 years
Headache: The Journal of Head and Face Pain · 2025
DOI: 10.1111/head.14943 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Andreas R Gantenbein und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurorehabilitation, Zurzach Care, Bad Zurzach, Switzerland. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Quality of Life, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma Schweiz AG.
Abstract (Originalsprache)
Objectives/Background This prospective, multicenter, noninterventional cohort study evaluated the impact of erenumab on the quality of life and migraine‐related impairment of adult patients with migraine, as well as the drug's tolerability in a real‐world setting over 2 years. Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide (CGRP) receptor, was licensed in Switzerland for prophylactic treatment of adult patients with migraine in July 2018.
Methods
Adult patients with chronic or episodic migraine who received erenumab treatment as per Swiss label were enrolled from 19 sites across Switzerland between February 2019 and November 2022. Inclusion criteria were defined as the following: a migraine diagnosis per International Classification of Headache Disorders, 3rd edition, patient written informed consent, and adherence to Swiss label guidelines. Exclusion criteria were concomitant use of other investigational drugs or prior treatment with erenumab or any CGRP (receptor)‐based therapy. Retrospective and prospective data from patients were collected over 24 months using patient‐reported outcome questionnaires (Headache Impact Test‐6 [HIT‐6], modified Migraine Disability Assessment [mMIDAS], Impact of Migraine on Partners and Adolescent Children [IMPAC]), patient diaries, and medical charts to track migraine days, medication use, and health care utilization. Swiss regulations required patients to maintain migraine diaries 3 months before and during erenumab therapy to record migraine and acute medication days.
Results
A total of 173 patients (84.9% females) were enrolled who had an average age of 44.2 years. Of these, 54.3% were diagnosed with episodic migraine and 45.7% with chronic migraine. At baseline, the participants scored 65.9 ± 4.9 (mean ± SD) on HIT‐6. A total of 85.5% had grade III–IV on the mMIDAS and 87% had grade III–IV in IMPAC. Patients reported 16.5 ± 7.2 monthly migraine days and 11.5 ± 7.0 acute migraine‐specific medication days per month. After 24 months, the mean HIT‐6 score had decreased by 8.1 ± 8.6, mean mMIDAS by 16.6 ± 21.2, monthly migraine days by 8.8 ± 7.6, and mean acute migraine‐specific medication days by 5.2 ± 6.8 (all p < 0.001). Reductions of IMPAC by 6.5 ± 6.6 ( p < 0.001) showed the beneficial impact of erenumab treatment on the patients' family burden attributed to migraine. Overall, 84 of 173 patients (48.6%) had at least one adverse event and 61 of 173 patients (35.3%) had at least one adverse event related to study drug. The safety profile was in line with the pivotal studies, and no serious adverse events were regarded as being related to erenumab.
Conclusion
Overall, erenumab treatment significantly reduced the burden of migraine, leading to improved quality of life for patients and their families over a treatment period of 2 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurorehabilitation, Zurzach Care, Bad Zurzach, Switzerland.
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
- Neurocenter, Luzerner Kantonsspital, Lucerne, Switzerland.
- Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
- Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
- Faculty of Biomedical Sciences, University of Southern Switzerland, Lugano, Switzerland.
ORCID-Profile: Christoph J Schankin, Heiko Pohl
Förderung
- Novartis Pharma Schweiz AG
Zitieren
APA
Gantenbein, A. R., Kamm, C. P., Schankin, C. J., Zecca, C., Zieglgänsberger, D., Pohl, H., Ryvlin, P., Agosti, R., Viceic, D., Parzini, C., Kulartz-Schank, M., & Arzt, M. E. (2025). Swiss Quality of Life and Health Care Impact Assessment in a Real‐World Erenumab‐Treated Migraine Population: Results over 2 years. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14943
Vancouver
Gantenbein AR, Kamm CP, Schankin CJ, Zecca C, Zieglgänsberger D, Pohl H, et al. Swiss Quality of Life and Health Care Impact Assessment in a Real‐World Erenumab‐Treated Migraine Population: Results over 2 years. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14943
BibTeX
@article{Gantenbein2025,
author = {Gantenbein, Andreas R and Kamm, Christian P and Schankin, Christoph J and Zecca, Chiara and Zieglgänsberger, Dominik and Pohl, Heiko and Ryvlin, Philippe and Agosti, Reto and Viceic, Dragana and Parzini, Catherine and Kulartz-Schank, Monika and Arzt, Michael E},
title = {Swiss Quality of Life and Health Care Impact Assessment in a Real‐World Erenumab‐Treated Migraine Population: Results over 2 years},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
doi = {10.1111/head.14943}
}
EUVIMED